Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 64
Healthy volunteers: yes

Brief summary:
BI 691751 is currently being developed to inhibit growth and prevent rupture of atherosclerotic plaques and to consequently reduce the risk of major cardiovascular events in patients with established atherosclerotic disease. 1334.5 is a Pan Asian Phase 1 study to investigate safety, tolerability and pharmacokinetics of BI 691751 in healthy Chinese and Japanese male volunteers.

Detailed description:

Arms:
arm 1: BI 691751 low dose 1 arm 2: BI 691751 low dose 2 arm 3: BI 691751 middle dose arm 4: BI 691751 high dose

Interventions: intervention 1: Placebo to BI 691751 intervention 2: BI 691751 high dose intervention 3: BI 691751 middle dose intervention 4: Placebo to BI 691751 intervention 5: BI 691751 low dose 1 intervention 6: Placebo to BI 691751 intervention 7: Placebo to BI 691751 intervention 8: BI 691751 low dose 2
Intervention descriptions: intervention 1: Placebo to BI 691751 intervention 2: BI 691751 high dose intervention 3: BI 691751 middle dose intervention 4: Placebo to BI 691751 intervention 5: BI 691751 low dose 1 intervention 6: Placebo to BI 691751 intervention 7: Placebo to BI 691751 intervention 8: BI 691751 low dose 2

Protocol document: